Simplify Logo

Full-Time

Sr. Scientist

Conjugation Development

Posted on 3/22/2024

Vaxcyte

Vaxcyte

201-500 employees

Develops broad-spectrum bacterial infection vaccines

Hardware
Biotechnology

Compensation Overview

$152k - $170k

Senior, Expert

San Carlos, CA, USA

Category
Lab & Research
Life Sciences
Physical Sciences
Requirements
  • PhD in Chemistry, Biochemistry, or related field with 5+ years of industry experience, MS with 8+ years, or BS with 10+ years of experience.
  • Strong biochemistry and organic chemistry knowledge base underpinning several years' experience preparing bioconjugates.
  • Subject matter expertise with small- and large-scale techniques for purification of bioconjugates, including tangential flow filtration.
  • Subject matter expertise with techniques for bioconjugate analysis such as colorimetric assays, HPLC, and SEC-MALS.
  • Sufficient knowledge of analytical principles to develop fit-for-purpose analytical methods as needed and provide cross-functional feedback on draft analytical methods.
  • Experience with Design of Experiments is desirable.
  • Experience with chemical modification of polysaccharides is desirable.
  • Experience implementing and/or using electronic notebooks is desirable.
Responsibilities
  • Optimize and troubleshoot multi-step syntheses of protein-polysaccharide conjugates.
  • Purify polysaccharides and conjugates using a variety of methods including dialysis, size-exclusion chromatography, and tangential flow filtration (TFF).
  • Analyze polysaccharides and conjugates with a variety of analytical methods.
  • Advise team members on experimental design, interpretation of results, and troubleshooting.
  • Model and train team members on best practices for adherence to protocols and data management.
  • Serve as a subject matter expert during tech transfer of conjugation processes to contract manufacturing organizations.
  • Maintain highly organized records to enable optimization and assessment of reproducibility.
  • Attend team meetings ready to provide updates on conjugation development progress.

Vaxcyte is centered on creating advanced vaccines such as VAX-24, a sophisticated 24-valent pneumococcal conjugate vaccine, by utilizing cutting-edge chemistry and the XpressCF™ cell-free protein synthesis platform. The company prioritizes developing high-fidelity, broad-spectrum vaccines to combat bacterial infections, continuously expanding its product pipeline with innovations like VAX-31 for various bacterial threats.

Company Stage

IPO

Total Funding

$2.3B

Headquarters

Foster City, California

Founded

2013

Growth & Insights
Headcount

6 month growth

25%

1 year growth

50%

2 year growth

120%
INACTIVE